January 20th 2025
The two companies will be exhibiting together after Gerresheimer’s December 2024 acquisition of Bormioli.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Zebrafish: a multifaceted approach for drug safety assessment
November 1st 2008Many compounds fail in preclinical development because of safety-related problems, but identifying 'predictable' safety or toxicity liabilities earlier in the process could lead to improved design and selection of compounds that are more likely to be approved.
Lawmakers Question FDA About DTC Website
October 23rd 2008Rep. John D. Dingell (D-MI), chairman of the US House of Representatives Committee on Energy and Commerce, and Rep. Bart Stupak (D-MI), chairman of the Oversight and Investigations Subcommittee, sent letters to the US Food and Drug Administration, Shaw Science Partners, and EthicAd to request information about a new FDA website.
SPL Now "Only Acceptable" Format for CBER Original Submissions
October 15th 2008According to a July 11, 2008 memorandum posted by the Center for Biologics Evaluation and Research, starting Oct. 15, Health Level 7 structured product labeling in XML (extensible markup language) will be the only acceptable presentation in electronic format for the submission of content of labeling that CBER can process, review, and archive.
MedPAC Recommends Public Disclosure of Payments to Physicians
October 15th 2008At a public meeting, the Medicare Payment Advisory Commission (MedPAC) discussed its recommendation that Congress establish a national database to publicly reveal financial relationships between physicians and the pharmaceutical industry.
Congress Probes FDA's Inspection Process of Actavis
October 15th 2008John Dingell (D-MI), chairman of the US House Committee on Energy and Commerce and Bart Stupak (D-MI), chairman of that committee's Subcomittee on Oversight and Investigations, directed a letter to US Food and Drug Administration Commissioner Andrew C. von Eschenbach to request further information regarding FDA's process for inspecting manufacturing facilities of the generic drug manufacturer Actavis following several product recalls by the company.
Keeping It Together: Reducing Powder Segregation in Vacuum Conveying
October 15th 2008Vacuum-conveying technology is commonly used in the pharmaceutical industry to move materials through the processing line, blend ingredients in various solutions, and handle tablets. The vacuum conveying of powders and granules, however, must be performed properly to avoid segregation, the separation of ingredients that results in an uneven mixture.